Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Atezolizumab + Carboplatin + Etoposide|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Atezolizumab||Tecentriq||RG7446|MPDL3280A||Immune Checkpoint Inhibitor 95 PD-L1/PD-1 antibody 59||Tecentriq (atezolizumab) is a monoclonal antibody against PD-L1 (CD274), preventing activation of its receptor, potentially enhancing T-cell-mediated immune response to neoplasms and inhibiting T-cell inactivation (PMID: 29449897). Tecentriq (atezolizumab) is FDA approved for use in patients with advanced urothelial carcinoma, metastatic non-small cell lung cancer (NSCLC) progressed on platinum-containing therapy, in combination with bevacizumab, paclitaxel, and carboplatin for non-squamous NSCLC with no EGFR or ALK aberrations, in combination with paclitaxel protein-bound for advanced or metastatic triple-negative breast cancer expressing PD-L1, and in combination with carboplatin and etoposide for small cell lung cancer (FDA.gov).|
|Carboplatin||Paraplatin||CBDCA||Chemotherapy - Platinum 6||Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary).|
|Etoposide||Vepesid||EPEG|Eposin||TOPO2 inhibitor 4||Vepesid (etoposide) binds to and inhibits DNA topoisomerase II, resulting in accumulated DNA damage, inhibition of replication, and cell death (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||lung small cell carcinoma||not applicable||Atezolizumab + Carboplatin + Etoposide||Guideline||Actionable||Tecentriq (atezolizumab), Paraplatin (carboplatin), and Vepesid (etoposide) combination treatment is included in guidelines as a preferred first-line systemic therapy for patients with advanced small cell lung cancer (NCCN.org).||detail...|
|Unknown unknown||lung small cell carcinoma||not applicable||Atezolizumab + Carboplatin + Etoposide||FDA approved||Actionable||In a Phase III trial (IMpower133) that supported FDA approval, Tecentriq (atezolizumab) in combination with Paraplatin (carboplatin) and Vepesid (etoposide) resulted in significantly improved median overall survival (12.3 vs 10.3 months, HR=0.70, p=0.007) and median progression-free survival (5.2 vs 4.3 months, HR=0.77, p=0.02) compared to placebo in patients with untreated extensive-stage small-cell lung cancer (PMID: 30280641; NCT02763579).||detail... 30280641|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT04256421||Phase III||Atezolizumab + Carboplatin + Etoposide + MTIG7192A Atezolizumab + Carboplatin + Etoposide||A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer (SKYSCRAPER-02)||Recruiting|
|NCT02748889||Phase Ib/II||Carboplatin + Etoposide Atezolizumab + Carboplatin + Etoposide||Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer||Terminated|
|NCT02763579||Phase III||Atezolizumab + Carboplatin + Etoposide Carboplatin + Etoposide||A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer (IMpower133)||Active, not recruiting|
|NCT03041311||Phase II||Atezolizumab + Carboplatin + Etoposide + Trilaciclib Atezolizumab + Carboplatin + Etoposide||Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Extensive Stage Small Cell Lung Cancer (SCLC)||Active, not recruiting|
|NCT03811002||Phase II||Atezolizumab + Carboplatin + Etoposide Atezolizumab + Cisplatin + Etoposide Cisplatin + Etoposide Carboplatin + Etoposide||Chemoradiation With or Without Atezolizumab in Treating Patients With Limited Stage Small Cell Lung Cancer||Recruiting|